SOS2-Targeting Oligonucleotides for Disease-Pathway Suppression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for improved therapeutics to treat chronic kidney disease, diabetic nephropathy, gout, hyperuricemia, hypertension, cerebrovascular disease, type 2 diabetes, metabolic syndrome, obesity, hyperlipidemia, hypertriglyceridemia, glaucoma, ocular hypertension, retinal diseases, age-related macular degeneration, choroidal neovascularization, geographic atrophy, diabetic retinopathy, non-alcoholic fatty liver disease, fibrotic liver disease, cirrhosis, and hair loss, as existing treatments are inadequate.
Innovation Solution
Compositions comprising oligonucleotides, such as siRNA or ASO, that target SOS2 to inhibit its expression, thereby reducing SOS2 mRNA and protein levels, and administering these compositions to subjects to achieve significant reductions in various disease-related parameters and improvements in kidney function and other health markers.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing treatments are used for SOS2-related diseases, then current standard of care is maintained, but therapeutic effectiveness is inadequate
Solution Approach 1:
The patent extracts and targets SOS2 specifically as the therapeutic intervention point. By using oligonucleotides (siRNA/ASO) to selectively reduce SOS2 expression, the invention isolates the harmful factor (SOS2 overexpression) and removes it from the disease pathway, achieving therapeutic effectiveness that exceeds existing treatments.
Solution Approach 2:
The patent changes the expression level parameter of SOS2 from elevated/dysregulated to reduced/normally regulated levels. Through oligonucleotide-mediated degradation of SOS2 mRNA, the invention transforms the molecular parameter of SOS2 expression, thereby improving therapeutic outcomes for multiple SOS2-related conditions.
2Reliability
If SOS2 expression is reduced by oligonucleotides, then disease parameters improve, but treatment complexity increases
Solution Approach 1:
The patent employs short-lived oligonucleotide molecules (siRNA/ASO) as the therapeutic agent. These molecules are designed to be transient and degradable, providing targeted SOS2 reduction without requiring complex long-term delivery systems. The oligonucleotides perform their function and are then degraded, simplifying the treatment profile compared to permanent genetic modifications or long-acting proteins.
3Adaptability or versatility
If oligonucleotides are administered to treat multiple SOS2-related conditions, then therapeutic versatility is achieved, but dosing and monitoring complexity increases
Solution Approach 1:
The patent establishes SOS2 as a universal therapeutic target across multiple disease indications including kidney disease, metabolic disorders, cardiovascular conditions, and ocular diseases. A single oligonucleotide-based approach can address diverse conditions by targeting the common SOS2 pathway, achieving versatility without requiring disease-specific molecular therapies.
Solution Approach 2:
The patent incorporates monitoring of SOS2 expression levels and disease-specific parameters to guide dosing and treatment duration. By measuring the reduction in SOS2 expression and corresponding improvements in disease markers, the invention enables adaptive dosing strategies that optimize therapeutic effectiveness while minimizing complexity in treatment management.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The oligonucleotides effectively decrease SOS2 mRNA and protein levels by 10% or more, leading to substantial improvements in kidney function, blood pressure, uric acid levels, intraocular pressure, and other disease-related parameters by 10% to 100% or more, providing therapeutic benefits for the mentioned conditions.
Implementation Method 1
an oligonucleotide that targets SOS2 and when administered to a subject in an effective amount increases an estimated glomerular filtration rate
Implementation Method 2
the oligonucleotide comprises a small interfering RNA (siRNA) comprising a sense strand and an antisense strand
Data Source
AI summary
Disclosed herein are compositions comprising an oligonucleotide that targets SOS Ras/Rho guanine nucleotide exchange factor 2 (SOS2). The oligonucleotide may include a small interfering RNA (siRNA) or an antisense oligonucleotide (ASO). Also provided herein are methods of treating conditions associated with SOS2 mutations that include providing an oligonucleotide that targets SOS2 to a subject.